GLP-1 + TRT: Managing Combination Therapy Programs at Scale

The Fastest-Growing Combination in Men's Health Clinics

Two years ago, most men's health telehealth clinics ran a single-protocol model: testosterone replacement therapy, prescribed as a weekly or biweekly injection, with quarterly lab monitoring and a simple renewal subscription. GLP-1 receptor agonists existed but were treated as a separate, often entirely different, service line. That separation is dissolving rapidly.

Today, the GLP-1 + TRT combination has become the highest-growth program category across men's health clinics. Survey data from clinic operators suggests that 35–55% of active TRT patients are either already on a GLP-1 agent or have expressed interest in adding one within their next subscription cycle. For new patients entering a men's health clinic in 2026, the combination inquiry rate at intake is frequently above 60%.

The drivers are straightforward: GLP-1 agents have crossed into mainstream consumer awareness following the explosive growth of branded semaglutide and tirzepatide products. Men who are already engaged with a TRT clinic — a relationship that signals willingness to proactively manage hormone and metabolic health — are the ideal demographic for GLP-1 adoption. They are already doing weekly injections. They are already monitoring labs. They already have a prescribing relationship with a provider who can evaluate GLP-1 candidacy.

For clinic operators, the combination program represents the highest-value product in their portfolio. Combination patients pay more per month, stay longer, and generate referrals at a higher rate than single-protocol patients. But the operational complexity is real — and clinics that try to bolt GLP-1 management onto a TRT workflow built for a single compound frequently run into quality of care problems that only surface when the patient population scales past 40–60 combination patients. For the foundational business model before adding combination programs, see the guide to launching a profitable TRT/HRT telehealth practice.

Clinical Rationale: Testosterone Optimization + Metabolic Health + Body Composition

The combination of GLP-1 receptor agonist therapy and TRT is not simply a commercial opportunity — it reflects a coherent clinical rationale rooted in the relationship between sex hormones, metabolic health, and body composition.

The Hypogonadism-Obesity Cycle

Low testosterone and obesity are bidirectionally linked. Excess adipose tissue, particularly visceral fat, upregulates aromatase enzyme activity — converting testosterone to estradiol and suppressing the hypothalamic-pituitary-gonadal (HPG) axis. The resulting hypogonadism then further impairs lipolysis, promotes fat accumulation, and reduces muscle protein synthesis. Patients caught in this cycle frequently present to TRT clinics with testosterone levels in the low-normal range (250–400 ng/dL), significant central adiposity, and the metabolic consequences of chronically elevated estradiol relative to testosterone.

TRT alone does not reliably break this cycle. While exogenous testosterone restores circulating levels, the underlying adipose-driven aromatase activity continues, often requiring higher testosterone doses and/or aromatase inhibitor co-prescription to maintain optimal ratios. The root cause — excess adipose tissue — persists.

GLP-1 receptor agonists address the cycle from the other direction. By suppressing appetite, slowing gastric emptying, and promoting satiety through central GLP-1 receptor signaling, they enable significant and sustained fat loss — typically 12–22% of body weight over 52–72 weeks, depending on compound and adherence. As visceral fat decreases, aromatase activity falls, the HPG axis recovers, and — critically — TRT becomes more efficient at delivering lean mass gains and hormonal optimization.

Body Composition: Where the Synergy Is Clearest

The most compelling clinical argument for the combination is body composition outcomes. GLP-1 agents produce significant weight loss, but a meaningful fraction of that weight loss in the absence of resistance training and adequate protein intake is lean mass — studies of semaglutide monotherapy report 25–40% of total weight loss coming from lean tissue. Testosterone directly counteracts this through anabolic signaling, increasing muscle protein synthesis and reducing the proportion of weight loss attributable to lean mass.

Patients on the combination who also engage in resistance training and follow protein-optimized nutrition guidance are increasingly demonstrating what metabolic medicine researchers have called "recomposition at scale" — simultaneous fat loss and lean mass gain that is rarely achieved through either protocol alone. For a patient demographic that is goal-oriented and motivated by visible results, this body composition outcome is a powerful retention driver.

Common GLP-1 Compounds Used Alongside TRT

Three GLP-1-adjacent compounds are driving the combination market. Each has a distinct mechanism, titration pattern, and operational requirement for the clinic managing the program.

Semaglutide

Semaglutide is a GLP-1 receptor agonist administered as a once-weekly subcutaneous injection. It is the dominant compound in the combination market due to its established clinical evidence base, widespread compounding availability, and relatively straightforward titration schedule. Average weight loss in clinical trials: 14–17% of body weight over 68 weeks. Compounded semaglutide is available from a range of 503B and 503A pharmacies and is currently the most commonly prescribed GLP-1 in the men's health telehealth channel.

Clinically relevant interaction with TRT: none known at the pharmacokinetic level. The primary consideration is nutritional — semaglutide's appetite suppression must be paired with protein intake guidance sufficient to support muscle protein synthesis in the presence of exogenous testosterone. Target: 0.8–1.2g of protein per pound of body weight daily.

Tirzepatide

Tirzepatide is a dual GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptor agonist, also administered once weekly. Its dual mechanism produces superior weight loss outcomes relative to semaglutide — clinical trials demonstrate 20–22% body weight reduction at the highest tolerated doses, with some patients achieving 25%+ loss. The GIP component adds a distinct effect on adipocyte metabolism that appears to enhance fat oxidation beyond GLP-1 signaling alone.

The higher weight loss magnitude makes tirzepatide particularly relevant for men presenting with significant obesity (BMI 35+) alongside hypogonadism. However, it also heightens the clinical importance of muscle preservation monitoring. Lab panels for tirzepatide patients should include regular assessment of lean mass markers, and titration should be coordinated with TRT dose stability review, as significant weight loss can shift SHBG levels and alter free testosterone bioavailability.

Retatrutide

Retatrutide is a triple-agonist compound targeting GLP-1, GIP, and glucagon receptors simultaneously. It is in late-stage clinical development and has demonstrated the highest weight loss outcomes of any compound in its class — Phase 2 data showed average weight reduction of 24% at 48 weeks, with some patients exceeding 30%. Compounded retatrutide is available through select 503A pharmacies and is increasingly available in forward-leaning men's health clinics as an ultra-premium offering.

The glucagon receptor agonism adds metabolic rate enhancement to the appetite suppression and satiety mechanisms of GLP-1/GIP — a meaningful differentiator for patients who have plateaued on semaglutide or tirzepatide. The compound commands higher pricing and requires careful patient selection; the combination with TRT for a morbidly obese, hypogonadal patient is the clearest clinical indication.

Protocol Comparison: TRT-Only vs. GLP-1-Only vs. Combination

Protocol Management Challenges

The clinical case for combination therapy is clear. The operational reality of managing it is significantly more complex than either protocol in isolation. Clinics that underestimate this complexity typically experience the consequences in one of three ways: patient safety events from missed lab monitoring, provider burnout from manual coordination overhead, or patient churn from poor communication about side effects and timeline expectations.

Different Titration Schedules Running in Parallel

TRT dosing is relatively static once dialed in. A patient typically starts at 100–150mg/week of testosterone cypionate, has their first 6-week labs drawn, adjusts dose based on total T, free T, hematocrit, and estradiol results, and then stabilizes on a maintenance dose that may only change if labs drift out of range or symptoms change. The titration arc spans weeks, not months.

GLP-1 titration runs on a completely different schedule. Semaglutide starts at 0.25mg/week for 4 weeks, escalates to 0.5mg for 4 weeks, then 1.0mg — with further titration to 1.7mg and 2.4mg based on tolerance and weight loss trajectory. Tirzepatide escalates in 2.5mg increments every 4 weeks. The titration arc spans months, and individual patients progress at different rates depending on GI tolerance, weight loss response, and personal preference.

Managing both tracks in a single patient record — with independent reminder schedules, different lab trigger points, and distinct clinical decision logic for each dose change — is not possible in a generic EMR or practice management system built for single-protocol workflows. For a comparison of platforms capable of handling this complexity, see the HRT clinic software comparison.

Overlapping Side Effects

Both TRT and GLP-1 agents carry distinct side effect profiles. When combined, some side effects overlap in ways that create diagnostic ambiguity for both patients and providers. The most clinically important overlapping effects:

• Fatigue: TRT initiation can cause transient fatigue during the first 4–6 weeks. GLP-1 agents cause nausea and fatigue, especially during dose escalation. A patient who started both within 60 days may not know which protocol is the source — and neither will the provider without protocol-specific symptom tracking.
• Gastrointestinal symptoms: GLP-1 agents commonly cause nausea, constipation, or loose stools during titration. Some patients on TRT also report GI sensitivity, particularly those on oral testosterone preparations. Accurate attribution matters for titration decisions.
• Mood changes: Both TRT (during initial hormone fluctuations) and GLP-1 agents (through central receptor effects, caloric restriction, and the psychological impact of rapid body composition change) affect mood. Providers need protocol-specific symptom logging to triage appropriately.
• Injection site reactions: Patients injecting both testosterone and a GLP-1 compound weekly need structured injection site rotation guidance to prevent lipohypertrophy, especially if using the same anatomical regions.

Separate Compounding Sources

Testosterone cypionate and compounded GLP-1 agents almost always originate from different compounding pharmacies. Not all 503B pharmacies are licensed for GLP-1 compounds; not all 503A pharmacies that compound semaglutide also compound testosterone in the concentrations a TRT clinic needs. Managing two separate Rx chains — with different refill schedules, different tracking portals, different patient-facing shipping timelines — multiplies coordination overhead for both the clinical and operations teams.

Dose Titration Coordination: GLP-1 Escalation While Maintaining Stable TRT Dosing

The core principle of combination titration management is: stabilize TRT before initiating GLP-1 escalation. Patients who are still in the TRT dose-finding phase — adjusting testosterone dose every 4–6 weeks based on labs — should not simultaneously be escalating their GLP-1 dose. Two moving variables produce ambiguous symptom and lab signal that makes clinical decision-making significantly harder. See the guide to testosterone lab tracking software for how automated lab result routing and flagging supports this dual-protocol monitoring requirement.

The recommended sequencing protocol: patients should be at least 8–12 weeks into TRT, on a stable dose with at least one lab confirmation of in-range total T, free T, hematocrit, and estradiol, before initiating a GLP-1 agent. In practice, many combination patients are existing TRT patients adding a GLP-1 agent — the sequencing is handled by the clinical history. For new patients presenting requesting both therapies simultaneously, the sequencing discipline is a clinical governance issue that software should enforce through workflow gatekeeping.

A critical titration decision point that many clinics handle incorrectly: if a patient loses more than 15% of body weight on a GLP-1 agent, SHBG levels often shift meaningfully, which changes the ratio of free to total testosterone. A patient who was optimized at 150mg/week of testosterone cypionate may find their free T falls out of optimal range as body composition changes — not because TRT is failing, but because the hormonal physiology has shifted. Labs should include SHBG at every 90-day draw for combination patients specifically to catch this.

Lab Monitoring for Combination Patients: The Expanded Panel

Standard TRT monitoring covers 6–8 markers. Standard GLP-1 monitoring covers a similar number. The combination panel is not simply additive — it is integrated, with some markers serving dual surveillance purposes and new markers required specifically because of the interaction between the two protocols.

Subscription Bundling: How to Price Combination Programs ($399–699/mo)

Combination therapy programs should be sold as bundled monthly subscriptions, not as two separate line-item protocols. The bundled model improves conversion, reduces churn, simplifies billing, and delivers a better patient experience. A patient who is manually managing two separate subscriptions to a TRT service and a GLP-1 service has two separate cancellation opportunities every month. A single bundled subscription is operationally simpler and psychologically stickier.

Pricing should include labs, patient visits, and both compounds in a single monthly charge. Clinics that charge separately for labs frequently experience lab compliance issues as patients decline lab orders to avoid the separate cost. When labs are included in the subscription, compliance rates approach 85–92% versus 55–65% when labs are billed separately. For how subscription billing mechanics work in practice, see the analysis of TRT subscription billing models.

An annual prepay option at a 10–15% discount is worth offering. A patient who prepays $5,400 for a year of TRT + Tirzepatide has effectively committed to the program for 12 months. Annual prepay patients churn at roughly one-quarter the rate of monthly subscribers.

Patient Communication: Managing Expectations, Timeline to Results, Side Effect Management

The single largest source of early combination program churn is unmanaged expectations. Patients starting a GLP-1 + TRT combination frequently have results timelines in their heads derived from social media content — "lost 40 pounds in 3 months" success stories that represent outliers, not medians. When week 8 arrives and they have lost 8 pounds instead of 20, and feel nauseated from semaglutide titration, and are still waiting to feel TRT's full effect, they cancel.

A Realistic Expectations Framework

Clinics that retain combination patients at high rates proactively communicate this timeline at onboarding and reinforce it through protocol-specific check-in messages:

• Weeks 1–4 (TRT initiation): Injections begin. Patients may notice mild injection site soreness. Energy and libido improvements typically lag 4–6 weeks. No dramatic changes expected yet. GLP-1 has not yet started.
• Weeks 5–8 (TRT stabilization / GLP-1 initiation): First TRT labs drawn. GLP-1 initiated at lowest dose. Appetite suppression begins. Nausea is common and expected at this stage — reassure patients it typically resolves within 2–4 weeks per dose step. Weight loss of 1–3 pounds in this window is appropriate at low doses.
• Months 3–4 (GLP-1 mid-titration): First meaningful weight loss becomes visible. TRT effects fully established — patients should notice improved energy, mood, and physical performance. Body composition begins shifting. Labs confirm optimization.
• Months 5–7 (full protocol dose / primary results window): Most patients at or near target GLP-1 dose. Cumulative weight loss of 10–18% is typical. Lean mass preservation distinguishing this from GLP-1 monotherapy. Patients who have been doing resistance training see visible muscle development alongside fat loss.
• Months 8–12+ (maintenance / consolidation): Weight loss continues at a slower pace. TRT dose may be re-evaluated if significant weight change has altered SHBG. Patients entering "maintenance mindset" — sustaining results rather than aggressively losing.

Inventory and Pharmacy Management: Multiple Compounds from Different Sources

Combination therapy programs require pharmacy management infrastructure that most TRT clinics were not built to handle. The operational requirements:

Dual Pharmacy Routing

Testosterone and GLP-1 compounds almost always originate from different compounding sources. Testosterone cypionate compounding is mature, widely licensed, and available from most 503B pharmacies. GLP-1 compounding is newer, more supply-constrained, and concentrated among a smaller set of 503A and 503B pharmacies that specialize in weight management compounds. A clinic's preferred testosterone pharmacy may not compound semaglutide. A clinic's preferred GLP-1 pharmacy may not compound testosterone in the concentrations needed for TRT.

Pharmacies must be mapped to compounds in the clinic's software, and prescriptions must route to the appropriate pharmacy automatically based on the compound being prescribed. Manual pharmacy routing — providers remembering which pharmacy handles which compound for each patient — does not scale and introduces prescription error risk at volume.

Refill Schedule Coordination

TRT prescriptions are typically dispensed in 10-week vials (10mL at standard concentrations) on a 10-week refill cycle. GLP-1 compounds are dispensed in 4-week or 8-week supply quantities depending on the compound and pharmacy. These cycles do not align. A patient's testosterone may refill in week 10 while their semaglutide refills in week 8 and week 16. Managing independent refill windows for 100+ patients across two pharmacies with a manual tracking system guarantees missed refills and patient frustration.

Inventory Forecasting

GLP-1 compounds, particularly tirzepatide, have experienced supply disruptions. Clinics that can forecast GLP-1 demand based on their patient population's titration schedules — how many patients are at 2.5mg vs. 5mg vs. 7.5mg this month — can work proactively with pharmacy partners to ensure supply. Clinics without this visibility discover supply shortages when patients run out.

Revenue Impact: Combination Patients Have 40–60% Higher LTV Than Single-Protocol

The revenue impact of combination programs is the most compelling business argument for investing in the operational infrastructure to manage them well. The data across clinic operators that have modeled this is consistent: combination therapy patients have 40–60% higher lifetime value than single-protocol patients, and they churn at roughly half the rate.

The revenue modeling also understates the combination patient's value because it excludes the referral premium. Combination patients who achieve visible body composition results — fat loss alongside muscle preservation — are the most likely patients to refer friends and colleagues. Men who refer typically bring in other men who are prime combination program candidates. Referral channels driven by satisfied combination patients have a 60–80% lower cost-per-acquisition than paid digital acquisition channels.

Technology Requirements for Managing Combination Programs at 100+ Patients

The inflection point at which spreadsheet-and-generic-EMR management of combination patients breaks down is approximately 40–60 patients. Below that threshold, a disciplined operations team can manage two protocol tracks per patient with manual processes. Above 60 combination patients, the combination of overlapping titration windows, dual lab tracking, dual pharmacy routing, and protocol-specific patient communication generates enough coordination overhead that manual management begins to produce clinical gaps.

At 100+ combination patients, dedicated software is not optional — it is a patient safety requirement. The technology stack must include:

The functional requirements for combination patient management software at scale:

• Unified patient chart with dual protocol display: Both active protocols visible in a single view — current dose, last injection date, next injection date, titration status, and next titration eligibility for each compound independently.
• Independent reminder schedules per compound: Weekly GLP-1 injection reminders and weekly or biweekly TRT injection reminders on separate cadences, with protocol-specific content (not a generic "time for your injection" message).
• Compound-specific lab panel tracking: The system must know which labs belong to which protocol, track each marker's due date independently, surface the combined panel for ordering, and alert when any marker is overdue — by protocol, not just globally.
• Multi-pharmacy prescription routing: Prescriptions route to the correct pharmacy per compound automatically. A unified Rx status view shows both active prescriptions regardless of which pharmacy is fulfilling them.
• Automated titration eligibility flagging: The system surfaces patients who are eligible for a GLP-1 dose increase based on weeks at current dose, weight loss trajectory, and documented tolerance — reducing provider time spent manually identifying who is ready to titrate.
• Bundled subscription billing: The billing layer must handle a single monthly charge that covers both protocols, with logic for what happens if one compound is paused (e.g., GLP-1 paused for surgery) without canceling the TRT subscription.
• Protocol-specific patient messaging: Automated check-in messages triggered by titration milestones ("You just completed week 4 at 0.25mg — here's what to expect on 0.5mg"), not generic appointment-based reminders.
• HIPAA-compliant data architecture: All patient records, lab results, and communications must comply with HIPAA minimum necessary standards, with audit logging for all access.